Biocon Q2 FY26 results, NCD redemption, CCD acquisition, CP issuance approved

Exceptional ItemResults View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹387.00

prior close

₹387.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.8%+3.9% vs market

Pharmaceuticals peers, median of 157sector+0.8%+3.9% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Midcap 150 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+0.9

15m

+0.2

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+0.8+3.9+0.8+3.9

Next day

+7.6+0.4+7.2+0.5+7.1

+6.3+0.5+5.8+0.4+6.0

+9.3+1.2+8.1+0.4+8.8

+8.9+0.5+8.4-0.1+9.1

+5.9+0.9+5.0-0.6+6.5

+2.7-0.3+3.0-1.2+3.9

15d

+6.1-0.4+6.5-1.8+7.9

-0.4-0.3-0.1-2.6+2.2

-4.2-1.2-2.9-5.4+1.2

-2.8+0.1-2.9-6.0+3.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 FY26 results. Consolidated revenue Rs 4,295 crore, up nearly 20% YoY from Rs 3,590 crore, PAT turned positive at about Rs 88 crore vs loss earlier. Biosimilars segment grew 25%. Also approved Rs 500 crore NCD redemption, Rs 300 crore CCD buyback of subsidiary BBL raising stake by about 65 basis points, and commercial paper issuance up to Rs 550 crore.

Likely market impact

Q2 turnaround with PAT returning to profit; capital actions reflect active debt management and BBL consolidation.